Adjuvant Tx Stage III-IV

› Forums › General Melanoma Community › Adjuvant Tx Stage III-IV

  • Post
    • October 31, 2013 at 7:17 pm
    SBeattie
    Participant

      Just wondering if anyone has any idea re: if/when PD-1 and combo with ipi  is FDA approved, it will be indicated for Stage III and IV 'resected' patients? I elected to watch/wait (the latter category) instead of enroll in the ipi 3mg or interferon trial, fearful of getting interferon (I know, if one doesn't try, then one will NEVER know) and fear of messing up getting into ipi-PD-1 trial if…more likely when, I may need it…unsights?

      Thank you all…

    Viewing 2 reply threads
    • Replies
        • October 31, 2013 at 7:22 pm
        Janner
        Participant

          Your best bet would be to look at the current Phase III clinical trials for the drug or combo.  If they are doing phase III clinical trials for adjuvant therapy, the drugs will probably be approved for such (that is if trials show benefit in an adjuvant setting).  But if all the trials are for people with active disease, it's more likely that the drug will have the same constraints when it is approved.  The trials are a pretty good indication of after market approval.

            • November 1, 2013 at 1:06 pm
            SBeattie
            Participant

              Thank you so much Janner!

              • November 1, 2013 at 1:06 pm
              SBeattie
              Participant

                Thank you so much Janner!

                • November 1, 2013 at 1:06 pm
                SBeattie
                Participant

                  Thank you so much Janner!

                • October 31, 2013 at 7:22 pm
                Janner
                Participant

                  Your best bet would be to look at the current Phase III clinical trials for the drug or combo.  If they are doing phase III clinical trials for adjuvant therapy, the drugs will probably be approved for such (that is if trials show benefit in an adjuvant setting).  But if all the trials are for people with active disease, it's more likely that the drug will have the same constraints when it is approved.  The trials are a pretty good indication of after market approval.

                  • October 31, 2013 at 7:22 pm
                  Janner
                  Participant

                    Your best bet would be to look at the current Phase III clinical trials for the drug or combo.  If they are doing phase III clinical trials for adjuvant therapy, the drugs will probably be approved for such (that is if trials show benefit in an adjuvant setting).  But if all the trials are for people with active disease, it's more likely that the drug will have the same constraints when it is approved.  The trials are a pretty good indication of after market approval.

                Viewing 2 reply threads
                • You must be logged in to reply to this topic.
                About the MRF Patient Forum

                The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

                The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

                Popular Topics